hims bpc 157 jumps more than 7% after an FDA panel recommends adding BPC-157 to the 503A compounding list potentially opening a new peptide category. The opportunity fits Hims existing telehealth, compounding and customer HIMS 🚨 THE VOTE FOR

3T3-L1 cells were cultured in 60 mm diameter dishes (8.4104 cells/dish) and treated with NNMT inhibitor dissolved in culture media with/without adipogenic factors (1 mM IBMX, 1 M dexamethasone, 10 g/ml of insulin) during each of the scheduled media changes during the differentiation process (described above)

Standard precaution for any peptide therapy

The sample is then sent to a state-certified laboratory for precise analysis

It was discovered more than 30 years ago, and in all that time, not one controlled human trial of it has been published

Patients who dont qualify for nutritional IV therapy include those who are breastfeeding or pregnant, as well as those with kidney failure, high blood pressure, and those going through active cancer treatment

Independent replication is limited